HRP20100293T1 - Formulacije za benzimidazolil piridil etere - Google Patents

Formulacije za benzimidazolil piridil etere Download PDF

Info

Publication number
HRP20100293T1
HRP20100293T1 HR20100293T HRP20100293T HRP20100293T1 HR P20100293 T1 HRP20100293 T1 HR P20100293T1 HR 20100293 T HR20100293 T HR 20100293T HR P20100293 T HRP20100293 T HR P20100293T HR P20100293 T1 HRP20100293 T1 HR P20100293T1
Authority
HR
Croatia
Prior art keywords
formulation
mixture
formulation according
compound
formula
Prior art date
Application number
HR20100293T
Other languages
English (en)
Croatian (hr)
Inventor
Hashash Ahmad
Ritchie Sean
Lin Kangwen
Shen Peng
Okhamafe Augustus
Gullapalli Rampurna
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20100293T1 publication Critical patent/HRP20100293T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20100293T 2006-07-21 2007-07-20 Formulacije za benzimidazolil piridil etere HRP20100293T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83271506P 2006-07-21 2006-07-21
PCT/US2007/016469 WO2008011154A2 (en) 2006-07-21 2007-07-20 Formulations for benzimidazolyl pyridyl ethers

Publications (1)

Publication Number Publication Date
HRP20100293T1 true HRP20100293T1 (hr) 2010-06-30

Family

ID=38819293

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100293T HRP20100293T1 (hr) 2006-07-21 2007-07-20 Formulacije za benzimidazolil piridil etere

Country Status (20)

Country Link
US (1) US8455662B2 (enExample)
EP (1) EP2046292B1 (enExample)
JP (1) JP2009544617A (enExample)
KR (1) KR20090033904A (enExample)
CN (1) CN101516335B (enExample)
AT (1) ATE459338T1 (enExample)
AU (1) AU2007275634B2 (enExample)
BR (1) BRPI0715423A2 (enExample)
CA (1) CA2657346A1 (enExample)
CY (1) CY1110037T1 (enExample)
DE (1) DE602007005139D1 (enExample)
DK (1) DK2046292T3 (enExample)
ES (1) ES2340631T3 (enExample)
HR (1) HRP20100293T1 (enExample)
MX (1) MX2009000770A (enExample)
PL (1) PL2046292T3 (enExample)
PT (1) PT2046292E (enExample)
RU (2) RU2452469C2 (enExample)
SI (1) SI2046292T1 (enExample)
WO (1) WO2008011154A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
PE20130814A1 (es) * 2006-08-30 2013-08-08 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
MX2009009344A (es) * 2007-03-02 2009-09-11 Novartis Ag Formas solidas de un inhibidor de cinasa raf.
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
JP5936609B2 (ja) * 2010-06-29 2016-06-22 ベラステム インコーポレイテッド キナーゼインヒビターの経口製剤
WO2012012139A1 (en) 2010-06-30 2012-01-26 Poniard Pharmaceuticals, Inc. Synthesis and use of kinase inhibitors
CN102336740B (zh) * 2010-07-27 2013-07-24 中国科学院上海药物研究所 一类咪唑类化合物及其用途
CN103301067B (zh) * 2012-03-15 2018-09-11 苏州泽璟生物制药有限公司 一种改善吸收性能的固体分散体及其制备
EP2976086B1 (en) 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
US10561627B2 (en) * 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
KR20220070057A (ko) 2015-03-09 2022-05-27 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
SG11201909046XA (en) 2017-04-03 2019-10-30 Coherus Biosciences Inc PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
IL127210A0 (en) 1996-05-23 1999-09-22 Applied Research Systems Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US6391683B1 (en) * 2000-06-21 2002-05-21 Siliconware Precision Industries Co., Ltd. Flip-chip semiconductor package structure and process for fabricating the same
US6756410B2 (en) 2000-08-30 2004-06-29 Kamal D. Mehta Induction of LDL receptor expression by extracellular-signal regulated kinase, ERK-1/2
TWI293877B (en) * 2000-09-20 2008-03-01 Rtp Pharma Inc Spray drying process and compositions of fenofibrate
US20040131670A1 (en) * 2001-04-17 2004-07-08 Ping Gao Pellicle-resistant gelatin capsule
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
DK1499311T3 (da) 2002-03-29 2010-03-08 Novartis Vaccines & Diagnostic Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
US20050082192A1 (en) * 2002-06-17 2005-04-21 Eric Smarr End cap support for jumbo rolls of material
US7846959B2 (en) * 2004-05-07 2010-12-07 Exelixis, Inc. Raf modulators and methods of use
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
US20100231394A1 (en) * 2009-03-11 2010-09-16 Bobby Eugene Finchum Carbon monoxide detection and dissipation apparatus

Also Published As

Publication number Publication date
CN101516335B (zh) 2014-01-08
EP2046292A2 (en) 2009-04-15
AU2007275634A1 (en) 2008-01-24
ATE459338T1 (de) 2010-03-15
PT2046292E (pt) 2010-04-26
WO2008011154A3 (en) 2008-06-26
RU2012107218A (ru) 2013-09-10
WO2008011154A2 (en) 2008-01-24
AU2007275634B2 (en) 2011-01-20
SI2046292T1 (sl) 2010-06-30
RU2009105819A (ru) 2010-08-27
EP2046292B1 (en) 2010-03-03
ES2340631T3 (es) 2010-06-07
CN101516335A (zh) 2009-08-26
JP2009544617A (ja) 2009-12-17
CA2657346A1 (en) 2008-01-24
MX2009000770A (es) 2009-01-28
DE602007005139D1 (de) 2010-04-15
CY1110037T1 (el) 2015-01-14
KR20090033904A (ko) 2009-04-06
RU2452469C2 (ru) 2012-06-10
DK2046292T3 (da) 2010-06-07
US20100040677A1 (en) 2010-02-18
PL2046292T3 (pl) 2010-08-31
US8455662B2 (en) 2013-06-04
BRPI0715423A2 (pt) 2013-07-02

Similar Documents

Publication Publication Date Title
HRP20100293T1 (hr) Formulacije za benzimidazolil piridil etere
HRP20140097T1 (hr) Farmaceutski sastav jakog hcv-inhibitora za oralnu primjenu
ES2531646T3 (es) Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
Bromberg et al. Effects of polyether-modified poly (acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers
WO2007098128A3 (en) Phenylephrine-containing liquid formulations
UA103906C2 (ru) Жидкая фармацевтическая композиция, которая содержит парацетамол
BR112012012789A2 (pt) formulações de ibuprofeno tópicas
ATE489942T1 (de) Ternäre nichtlamellare lipidzusammensetzungen
AR086115A1 (es) Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilos y los metodos para la preparacion y el uso de las mismas
DK2055711T3 (da) Anvendelse af squalensyre til formulering af et aktivt stof i nanopartikeltilstand
BR112013003581A2 (pt) formulação farmacêutica ou nutracêutica gastro resistente que compreende um ou mais sais do ácido algínico
WO2005110398A3 (en) Pharmaceutical solution formulations containing 17-aag
PH12014502609B1 (en) Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
ATE522204T1 (de) Beschichtete pellets
KR20140035879A (ko) 함수계 첩부제
HRP20160187T1 (hr) Tekući nazalni sprej koji sadrži nisku dozu naltreksona
NZ601528A (en) A low solvent carrier composition for delivery of biologically active compounds
EP2100661A3 (en) Cyclopropene complex compositions
WO2013191187A1 (ja) 薬剤と有機溶媒と親油性膏体基剤と粉体を配合した貼付製剤組成物
ES2457519T3 (es) Pasta a base de agua que contiene diclofenaco sódico
KR20170142159A (ko) 파프제
WO2009072334A1 (ja) 製剤用核粒子
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
KR101606950B1 (ko) 케토프로펜리신염을 함유하는 수성 첩부제
CA2791779A1 (en) Spill resistant formulations containing clays